ResMed Inc. (RMD) — Analyst outlook / Analyst consensus target is. Based on 35 analyst ratings, the consensus is bullish — 16 Buy, 14 Hold, 5 Sell.
The consensus price target is $295.88 (low: $265.00, high: $345.00), representing an upside of 28.3% from the current price $230.69.
Analysts estimate Earnings Per Share (EPS) of $7.73 and revenue of $4.68B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $6.94 vs est $7.73 (missed -10.2%). 2025: actual $9.55 vs est $9.51 (beat +0.4%). Analyst accuracy: 94%.
RMD Stock — 12-Month Price Forecast
$295.88
▲ +28.26% Upside
Average Price Target
Based on 35 Wall Street analysts offering 12-month price targets for ResMed Inc., the average price target is $295.88, with a high forecast of $345.00, and a low forecast of $265.00.
The average price target represents a +28.26% change from the last price of $230.69.
Highest Price Target
$345.00
Average Price Target
$295.88
Lowest Price Target
$265.00
RMD Analyst Ratings
Buy
Based on 35 analysts giving stock ratings to ResMed Inc. in the past 3 months
EPS Estimates — RMD
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $6.94
vs Est $7.73
▼ 11.3% off
2025
Actual $9.55
vs Est $9.51
▲ 0.4% off
Profitability Outlook
Strong profitability with high earnings per share. EPS trend is improving.
Revenue Estimates — RMD
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $4.685B
vs Est $4.680B
▲ 0.1% off
2025
Actual $5.146B
vs Est $5.128B
▲ 0.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
